Biotech One joins France BioLead
26 June 2026
Biotech One has joined France BioLead to contribute to the production of biopharmaceuticals in France.
With EncapX®, its millifluidic encapsulation technology, the company brings a building block for the formulation of nanoparticles, nanoliposomes and LNPs. The difference it states is a continuous approach, designed to scale and to limit the clogging risks seen in microfluidics.
The company places that difference against a major need of next-generation therapies: RNA, sensitive biomolecules, biotherapies and advanced formulations. It thanked France BioLead for its confidence.
Related news
Biotech One joins ETPN, the European Technology Platform on Nanomedicine
A European network of researchers, biotech companies and industrial partners. New collaborations, and nanoencapsulation closer to clinical needs.
4 November 2026
EncapX® presented to the AFSSI life sciences community
A continuous millifluidic platform to encapsulate active ingredients in nanoliposomes and LNPs precisely, reproducibly and at scale.
8 July 2026
Biotech One joins AFSSI Sciences de la Vie
Biotech One joins AFSSI Sciences de la Vie, the French association of companies partnering in preclinical research, development and health innovation.
11 June 2026